Regenerative Medical Technology Group INC
Market Movers (8-K)
OID
Regenerative Medical Technologies Group announces a 67% increase in Q1 2025 sales compared to Q1 2024, along with achieving an operating profit of $134,000 for the quarter.
Better than expected
OID
8-K: Regenerative Medical Technology Group Achieves Operational Profitability and 52% Sales Growth in Q3
Regenerative Medical Technology Group (RMTG) reports achieving operational profitability and a 52% year-over-year sales increase in Q3, alongside a 75% gross profit margin.
Better than expected
OID
Meso Numismatics Inc. has completed its name and ticker symbol change to Regenerative Medical Technology Group Inc. (RMTG), effective October 21, 2024.
OID
Meso Numismatics Inc. is transitioning to Regenerative Medical Technology Group Inc. and reported positive operating cash flow for the quarter ended March 31, 2024.
Better than expected
Quarterly Earnings (10-Q)
OID
Regenerative Medical Technology Group reported a 93.45% revenue increase for Q1 2026, though substantial debt and going concern doubts persist.
Better than expected
Capital raise
OID
Regenerative Medical Technology Group Inc. reported increased revenue but a significantly higher net loss for Q3 2025, driven by rising interest expenses and debt extinguishment losses, while facing substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Delay expected
OID
Regenerative Medical Technology Group Inc. reported significant revenue growth in Q2 2025, but faces severe financial distress with a substantial accumulated deficit and numerous defaulted loans, raising going concern doubts.
Delay expected
Worse than expected
Capital raise
OID
Regenerative Medical Technology Group Inc. saw a significant revenue increase in Q1 2025 compared to the previous year, but the company still reported a net loss and faces substantial financial challenges.
Delay expected
Worse than expected
Capital raise
OID
Regenerative Medical Technology Group Inc. saw a significant increase in revenue in the third quarter of 2024, but continues to operate with a substantial working capital deficit and faces challenges related to debt and going concern.
Worse than expected
Capital raise
OID
10-Q: Meso Numismatics Reports Increased Revenue but Continues to Face Losses and Debt Issues in Q2 2024
Meso Numismatics, Inc. reports a revenue increase for Q2 2024 but continues to struggle with net losses, substantial debt, and going concern uncertainties.
Worse than expected
Capital raise
Annual Reports (10-K)
OID
Regenerative Medical Technology Group reports 24% revenue growth for 2025 while highlighting significant going concern risks.
Worse than expected
Delay expected
Capital raise
OID
Regenerative Medical Technology Group's annual report highlights a 70.44% revenue increase in 2024 and details strategic initiatives for continued expansion in 2025.
Worse than expected
Capital raise
Delay expected
OID
Meso Numismatics, Inc. reports a significant 57% revenue increase in 2023, primarily driven by its Global Stem Cells Group operations, despite a net loss of $9.8 million.
Worse than expected
Capital raise